Cubist Systematic Strategies LLC Takes Position in Haleon plc (NYSE:HLN)

Cubist Systematic Strategies LLC purchased a new stake in Haleon plc (NYSE:HLN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 421,631 shares of the company's stock, valued at approximately $4,022,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Procyon Advisors LLC grew its position in shares of Haleon by 41.3% in the fourth quarter. Procyon Advisors LLC now owns 230,240 shares of the company's stock valued at $2,196,000 after purchasing an additional 67,329 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Haleon by 29.8% in the fourth quarter. Bank of New York Mellon Corp now owns 2,071,017 shares of the company's stock valued at $19,758,000 after purchasing an additional 475,934 shares during the last quarter. SeaCrest Wealth Management LLC acquired a new stake in shares of Haleon in the fourth quarter valued at about $102,000. Atria Wealth Solutions Inc. grew its position in shares of Haleon by 6.1% in the fourth quarter. Atria Wealth Solutions Inc. now owns 47,868 shares of the company's stock valued at $457,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its position in shares of Haleon by 13.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 850,563 shares of the company's stock valued at $8,114,000 after purchasing an additional 99,666 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Price Performance

NYSE HLN traded up $0.28 during trading on Thursday, reaching $10.68. 20,036,212 shares of the company traded hands, compared to its average volume of 7,983,025. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock's 50 day moving average price is $10.21 and its two-hundred day moving average price is $9.85. The company has a market cap of $48.15 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 2.82 and a beta of 0.24. Haleon plc has a 1-year low of $8.25 and a 1-year high of $10.85.

Haleon (NYSE:HLN - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. The company had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Haleon had a return on equity of 14.76% and a net margin of 10.85%. As a group, analysts anticipate that Haleon plc will post 0.43 EPS for the current year.

Haleon Increases Dividend

The company also recently announced a -- dividend, which will be paid on Thursday, June 5th. Stockholders of record on Friday, April 25th will be paid a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. This is a boost from Haleon's previous -- dividend of $0.05. Haleon's payout ratio is 58.97%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target on the stock in a research report on Friday, May 9th. HSBC reissued a "hold" rating on shares of Haleon in a research report on Wednesday, March 5th. Hsbc Global Res downgraded Haleon from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, March 5th. Barclays reissued an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Five investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $11.25.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.